Report: China’s Innovent prices domestic PD-1 inhibitor at smaller discount than Junshi

Innovent priced its anti-PD-1 mAb Tyvyt in China at a discount compared with the China price of Keytruda, but a premium to the price of fellow domestic PD-1 inhibitor Tuoyi from Junshi Biosciences, according to a Goldman Sachs note.

Innovent Biologics Inc. (HKSE:1801) set the price of Tyvyt sintilimab (IBI308) at RMB7,838 ($1,169.75) per 100 mg, according to Goldman Sach's Ziyi Chen, which is a 56% discount compared with Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) at RMB17,918 ($2,671.38) per 100 mg. On a per-milligram basis, the Tyvyt price is a 161% premium compared with Tuoyi toripalimab from Shanghai Junshi Biosciences Co. Ltd. (HKSE:1877) at RMB7,200 ($1,073.44) per 240 mg (see "China's Junshi Prices Domestic Anti-PD-1 mAb at Deep Discount")...